Menu
Svensk version

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

Lund, Sweden, 31st August 2017 - During August, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased due to the exercise of warrants. As of August 31, 2017, the number of shares and votes in BONESUPPORT HOLDING AB (publ) amounts to 49,382,244.

 

About BONESUPPORT®

BONESUPPORT is an innovative and rapidly growing commercial stage orthobiologics company, based in Lund, Sweden. The Company develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs directly into the bone void. BONESUPPORT’s marketed bio-ceramic bone graft substitutes CERAMENT® BONE VOID FILLER (BVF), CERAMENT® G* and CERAMENT® V* are all based on the Company’s novel and proprietary CERAMENT technology platform.

The Company’s products are targeting a large addressable market opportunity across trauma, chronic osteomyelitis (bone infection), revision arthroplasty (replacement of a joint prosthesis) and infected diabetic foot.

BONESUPPORT’s total sales increased from SEK 41 million in 2014 to SEK 105 million in 2016, representing a compound annual growth rate of 60 percent. The Company’s financial target is to achieve revenue exceeding SEK 500 million in the financial year 2020, with a gross margin exceeding 85 percent and a positive operating profit.

The Company’s research and development is focused on the continuing development and refinement of its CERAMENT technology to extend its use into additional indications by the elution of other drugs and therapeutic agents. The Company currently has a pipeline of pre-clinical product candidates that have been designed to promote bone growth.

BONESUPPORT is listed on Nasdaq Stockholm and trades under the ticker “BONEX” (ISIN code: SE0009858152). Further information is available at www.bonesupport.com

*CERAMENT G: Not available in the United States, for investigational use only. CERAMENT V: Not available in the United States.

BONESUPPORT™ and CERAMENT™ are registered trademarks.

 

For more information contact:

Richard Davies, CEO

Tel: +46 (0) 46 286 53 71

 

Björn Westberg, CFO

Tel: +46 (0) 46 286 53 60

Email: ir@bonesupport.com

The information in the press release is such that BONESUPPORT HOLDING AB (publ) is required to disclose pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 18:00 CET on August 31, 2017.

Downloads

Press release PDF (408.76 KB)

BONESUPPORT, Mon Aug 7, 2017

BONESUPPORT is a #medtech company dedicated to development of injectable osteoconductive biomaterials https://t.co/SZVyGV3pkq

BONESUPPORT, Fri Aug 4, 2017

BONESUPPORT is a Scandinavian #medtech company dedicated to development of injectable osteoconductive biomaterials, https://t.co/SZVyGULOsS

BONESUPPORT, Tue Jul 4, 2017

BONESUPPORT is a Scandinavian #medtech company dedicated to development of injectable osteoconductive biomaterials, https://t.co/SZVyGULOsS